# Cellectis S.A.: overview

CLLS · Nasdaq · CIK 1627281 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/clls.md) · [Financials](/companies/clls/financials.md) · [Filings](/companies/clls/filings.md) · [Insiders](/companies/clls/insiders.md)

Revenue is not reported in this company’s XBRL financial statements.

## Last eight quarters

| Line item | Unit | period not labelled (2023-06-30) | period not labelled (2023-09-30) | Q4 FY2023 (2023-12-31) |
| --- | --- | ---: | ---: | ---: |
| Revenue | $ | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(0.20)](/filings/0000950170-24-050016.md) | not reported | not reported |
| Free cash flow | $ | not reported | not reported | not reported |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: ifrs-full:ProfitLossFromOperatingActivities. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLossAttributableToOwnersOfParent. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare.
- Free cash flow (operating cash flow − capital expenditure). XBRL not reported.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [30.3](/filings/0000950170-24-050016.md) | [19.2](/filings/0000950170-25-039038.md) | [0.8](/filings/0001193125-26-116428.md) | [41.5](/filings/0001193125-26-116428.md) | [72.9](/filings/0001193125-26-116428.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(341.0%)](/filings/0000950170-24-050016.md) | [(467.7%)](/filings/0000950170-25-039038.md) | [(12887.7%)](/filings/0001193125-26-116428.md) | [(143.5%)](/filings/0001193125-26-116428.md) | [(45.3%)](/filings/0001193125-26-116428.md) |
| Net margin | % | [(376.3%)](/filings/0000950170-24-050016.md) | [(553.6%)](/filings/0000950170-25-039038.md) | [(13385.3%)](/filings/0001193125-26-116428.md) | [(88.6%)](/filings/0001193125-26-116428.md) | [(92.7%)](/filings/0001193125-26-116428.md) |
| Diluted EPS | $ per share | [(2.55)](/filings/0000950170-24-050016.md) | [(2.33)](/filings/0000950170-25-039038.md) | [(1.77)](/filings/0001193125-26-116428.md) | [(0.41)](/filings/0001193125-26-116428.md) | [(0.67)](/filings/0001193125-26-116428.md) |
| Free cash flow | $m | [(123)](/filings/0000950170-24-050016.md) | [(89.9)](/filings/0000950170-25-039038.md) | [(25.8)](/filings/0001193125-26-116428.md) | [20.4](/filings/0001193125-26-116428.md) | [(41.8)](/filings/0001193125-26-116428.md) |

- Revenue. XBRL Revenue: ifrs-full:Revenue.
- Gross margin (gross profit / revenue). XBRL Revenue: ifrs-full:Revenue.
- Operating margin (operating income / revenue). XBRL Operating income: ifrs-full:ProfitLossFromOperatingActivities; Revenue: ifrs-full:Revenue.
- Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLossAttributableToOwnersOfParent; Revenue: ifrs-full:Revenue.
- Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities; Capital expenditure: ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/clls/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [B Group, Inc.](/funds/2043476.md) | 2026-06-30 | $9.8m | 3,281,501 |  | Unchanged |
| [Long Focus Capital Management, LLC](/funds/1602716.md) | 2026-06-30 | $8.2m | 2,741,853 |  | Reduced −2,245 |
| [UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC](/funds/861177.md) | 2026-06-30 | $7.9m | 2,644,881 |  | Reduced −533,739 |
| [NOMURA ASSET MANAGEMENT INTERNATIONAL INC.](/funds/921739.md) | 2026-06-30 | $681.0k | 226,875 |  | Unchanged |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $676.3k | 225,444 |  | Reduced −116,079 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $256.4k | 85,455 |  | Reduced −1,321 |
| [LPL Financial LLC](/funds/1403438.md) | 2026-06-30 | $253.2k | 84,415 |  | Added +70 |
| [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $151.4k | 50,453 |  | Reduced −15,489 |
| [BNP PARIBAS FINANCIAL MARKETS](/funds/1166588.md) | 2026-06-30 | $120.3k | 40,100 |  | Reduced −900 |
| [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $101.8k | 33,926 |  | Added +4,152 |

## Recent filings

[All 528 filings](/companies/clls/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-28 | 06:00 ET | [6-K](/filings/0001171843-26-006873.md) | Report of a foreign private issuer, period 2026-10-27 | 0001171843-26-006873 |
| 2026-09-14 | 06:00 ET | [6-K](/filings/0001171843-26-006010.md) | Report of a foreign private issuer, period 2026-09-14 | 0001171843-26-006010 |
| 2026-09-11 | 16:35 ET | [6-K](/filings/0001171843-26-006002.md) | Report of a foreign private issuer, period 2026-09-11 | 0001171843-26-006002 |
| 2026-09-01 | 16:35 ET | [6-K](/filings/0001171843-26-005837.md) | Report of a foreign private issuer, period 2026-09-01 | 0001171843-26-005837 |
| 2026-08-06 | 16:35 ET | [6-K](/filings/0001171843-26-005324.md) | Report of a foreign private issuer, period 2026-08-06 | 0001171843-26-005324 |
| 2026-08-06 | 16:30 ET | [6-K](/filings/0001193125-26-338220.md) | Report of a foreign private issuer, period 2026-08-06 | 0001193125-26-338220 |
| 2026-07-30 | 16:35 ET | [6-K](/filings/0001171843-26-005091.md) | Report of a foreign private issuer, period 2026-07-30 | 0001171843-26-005091 |
| 2026-06-25 | 16:35 ET | [6-K](/filings/0001171843-26-004304.md) | Report of a foreign private issuer, period 2026-06-25 | 0001171843-26-004304 |
| 2026-06-25 | 16:30 ET | [6-K](/filings/0001193125-26-282865.md) | Report of a foreign private issuer, period 2026-06-25 | 0001193125-26-282865 |
| 2026-06-11 | 07:00 ET | [6-K](/filings/0001171843-26-004051.md) | Report of a foreign private issuer, period 2026-06-11 | 0001171843-26-004051 |

## Latest annual report

[Form 20-F for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-116428.md), filed Mar 20, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1627281
- Tickers: CLLS
- Exchange: Nasdaq
- SIC code: 2836 Biological Products, (No Diagnostic Substances)
- State of incorporation: I0
- Filer category: Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 28, 2026, 06:05 ET. No prices; not investment advice.